Key facts
- This page summarizes David E. Lazar's Form 3 filing for Tracon Pharmaceuticals, Inc..
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 May 2024, 17:00.
David E. Lazar - 07 May 2024 Form 3 Insider Report for Tracon Pharmaceuticals, Inc.
- Reporting relationship
- Chief Business Dev Officer
- Issuer ticker
- N/A
- Reported as of
- 07 May 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 13 May 2024, 17:00:43 UTC
- Prior SEC filing
- 25 Apr 2024
- Next SEC filing
- 01 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott B. Brown, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Lazar filed Form 3 for Tracon Pharmaceuticals, Inc. on 13 May 2024.
Change
- Previous filing in this sequence was filed on 25 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
No securities are beneficially owned.